[1]
|
Hayes, D.F. (2019) HER2 and Breast Cancer—A Phenomenal Success Story. New England Journal of Medicine, 381, 1284-1286. https://doi.org/10.1056/NEJMcibr1909386
|
[2]
|
Yan, M., Schwaederle, M., Arguello, D., Millis, S.Z., Gatalica, Z. and Kurzrock, R. (2015) HER2 Expression Status in Diverse Cancers: Review of Results from 37,992 Patients. Cancer and Metastasis Reviews, 34, 157-164. https://doi.org/10.1007/s10555-015-9552-6
|
[3]
|
Najjar, S. and Allison, K.H. (2022) Updates on Breast Biomarkers. Virchows Archiv, 480, 163-176. https://doi.org/10.1007/s00428-022-03267-x
|
[4]
|
Kanayama, K., Imai, H., Usugi, E., Shiraishi, T., Hirokawa, Y.S. and Watanabe, M. (2018) Association of HER2 Gene Amplification and Tumor Progression in Early Gastric Cancer. Virchows Archiv, 473, 559-565. https://doi.org/10.1007/s00428-018-2433-y
|
[5]
|
Subramanian, J., Katta, A., Masood, A., Vudem, D.R. and Kancha, R.K. (2019) Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers. The Oncologist, 24, e1303-e1314. https://doi.org/10.1634/theoncologist.2018-0845
|
[6]
|
Sato, H., Offin, M., Kubota, D., Yu, H.A., Wilhelm, C., SToyooka, S., Somwar, R., Kris, M.G. and Ladanyi, M. (2021) Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. Journal of Thoracic Oncology, 16, 113-126. https://doi.org/10.1016/j.jtho.2020.09.019
|
[7]
|
Van Bockstal, M.R., Agahozo, M.C., van Marion, R., Atmodimedjo, P.N., Sleddens, H.F.B.M., Dinjens, W.N.M., Visser, L.L., Lips, E.H., Wesseling, J. and van Deurzen, C.H.M. (2020) Somatic Mutations and Copy Number Variations in Breast Cancers with Heterogeneous HER2 Amplification. Molecular Oncology, 14, 671-685. https://doi.org/10.1002/1878-0261.12650.
|
[8]
|
Yonesaka, K. (2021) HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. Cancers, 13, Article No. 1047. https://doi.org/10.3390/cancers13051047
|
[9]
|
Skidmore, L., Sakamuri, S., Knudsen, N.A., Hewet, A.G., Milutinovic, S., Barkho, W., et al. (2020) ARX788, a Site-Specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-Low and T-DM1-Resistant Breast and Gastric Cancers. Molecular Cancer Therapeutics, 19, 1833-1843. https://doi.org/10.1158/1535-7163.MCT-19-1004
|
[10]
|
Gandullo-Sánchez, L., Capone, E., Ocana, A., Iacobelli, S., Sala, G. and Pandiella, A. (2020) HER3 Targeting with an Antibody-Drug Conjugate Bypasses Resistance to Anti-HER2 Therapies. EMBO Molecular Medicine, 12, e11498. https://doi.org/10.15252/emmm.201911498
|
[11]
|
Tsurutani, J., Iwata, H., Krop, I., Janne, P.A., Doi, T., Takahashi, S., Park, H., et al. (2020) Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery, 10, 688-701. https://doi.org/10.1158/2159-8290.CD-19-1014
|
[12]
|
Thuss-Patience, P.C., Shah, M.A., Ohtsu, A., Van Cutsem, E., Ajani, J.A., Castro, H., Mansoor, W., Chung, H.C., Bodoky, G., Shitara, K., Phillips, G.D.L., van der Horst, T., Harle-Yge, M.L., Althaus, B.L. and Kang, Y.-K. (2017) Trastuzumab Emtansine Versus Taxane Use for Previously Treated HER2-Positive Locally Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GATSBY): An International Randomised, Open-Label, Adaptive, Phase 2/3 Study. The Lancet Oncology, 18, 640-653. https://doi.org/10.1016/S1470-2045(17)30111-0
|
[13]
|
Shitara, K., Bang, Y.J., Iwasa, S., Sugimoto, N., Ryu, M.H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., Saito, K., Kawaguchi, Y., Kamio, T., Kojima, A., Sugihara, M. and Yamaguchi, K. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine, 382, 2419-2430. https://doi.org/10.1056/NEJMoa2004413
|
[14]
|
Shitara, K., et al. (2019) Trastuzumab Deruxtecan (DS-8201a) in Patients with Advanced HER2-Positive Gastric Cancer: A Dose-Expansion, Phase 1 Study. The Lancet Oncology, 20, 827-836. https://doi.org/10.1016/S1470-2045(19)30088-9
|
[15]
|
von Arx, C., De Placido, P., Caltavituro, A., et al. (2023) The Evolving Therapeutic Landscape of Trastuzumab-Drug Conjugates: Future Perspectives beyond HER2-Positive Breast Cancer. Cancer Treatment Reviews, 113, Article ID: 102500. https://doi.org/10.1016/j.ctrv.2022.102500
|
[16]
|
Shi, F., Liu, Y., Zhou, X., Shen, P., Xue, R. and Zhang, M. (2022) Disitamab Vedotin: A Novel Antibody-Drug Conjugates for Cancer Therapy. Drug Delivery, 29, 1335-1344. https://doi.org/10.1080/10717544.2022.2069883
|
[17]
|
Peng, Z., Liu, T., Wei, J., Wang, A., He, Y., Yang, L., Zhang, X., et al. (2021) Efficacy and Safety of a Novel Anti-HER2 Therapeutic Antibody RC48 in Patients with HER2-Overexpressing, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer: A Single-Arm Phase II Study. Cancer Communications, 41, 1173-1182. https://doi.org/10.1002/cac2.12214
|
[18]
|
Deeks, E.D. (2021) Disitamab Vedotin: First Approval. Drugs, 81, 1929-1935. https://doi.org/10.1007/s40265-021-01614-x
|
[19]
|
Xu, Y., Wang, Y., Gong, J., Zhang, X., Peng, Z., Sheng, X., Mao, C., et al. (2021) Phase I Study of the Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate RC48-ADC in Patients with HER2-Positive Advanced Solid Tumors. Gastric Cancer, 24, 913-925. https://doi.org/10.1007/s10120-021-01168-7
|
[20]
|
Huang, L., Wang, R., Xie, K., Zhang, J., Tao, F., Pi, C., Feng, Y., Gu, H. and Fang, J. (2022) A HER2 Target Antibody Drug Conjugate Combined with Anti-PD-(L)1 Treatment Eliminates HHER2+ Tumors in HPD-1 Transgenic Mouse Model and Contributes Immune Memory Formation. Breast Cancer Research and Treatment 191, 51-61. https://doi.org/10.1007/s10549-021-06384-4
|
[21]
|
(2019) ZW25 Effective in HER2-Positive Cancers. Cancer Discovery, 9, 8. https://doi.org/10.1158/2159-8290.CD-NB2018-162
|
[22]
|
Meric-Bernstam, F., et al. (2022) Zanidatamab, a Novel Bispecific Antibody, for the Treatment of Locally Advanced or Metastatic HER2-Expressing or HER2-Amplified Cancers: A Phase 1, Dose-Escalation and Expansion Study. The Lancet Oncology, 23, 1558-1570. https://doi.org/10.1016/S1470-2045(22)00621-0
|
[23]
|
Jhaveri, K., et al. (2022) Preliminary Results from a Phase I Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-Targeting Antibody-Drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers. Annals of Oncology, 33, S749-S750. https://doi.org/10.1016/j.annonc.2022.07.589
|
[24]
|
Gong, J., Shen, L., Dong, Z., Liu, D., Xu, J., Yang, J., Yang, Y., et al. (2020) 810 Preliminary Safety, Tolerability and Efficacy Results of KN026 in Combination with KN046 in Patients with HER2 Aberrated Solid Tumors. Journal for ImmunoTherapy of Cancer, 8, A485-A486. https://doi.org/10.1136/jitc-2020-SITC2020.0810
|
[25]
|
Banerji, U., van Herpen, C.M.L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I.R., Boni, V., Rolfo, C., de Vries, E.G.E., Rottey, S., Geenen, J., Eskens, F., Gil-Martin, M., Mommers, E.C., Koper, N.P. and Aftimos, P. (2019) Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study. The Lancet Oncology, 20, 1124-1135. https://doi.org/10.1016/S1470-2045(19)30328-6
|
[26]
|
Wang, N., Wang, Z.W., Mei, Q.Y., Zhao, L., Zhang, D. and Kong, F.M. (2022) Research Progress of Clinical Application of Antibody-Coupled Drugs in HER2-Positive Gastric Cancer. Chinese Cancer Clinics, No. 19, 1009-1014. (In Chinese)
|
[27]
|
Dragovich, P.S. (2022) Degrader-Antibody Conjugates. Chemical Society Reviews, 51, 3886-3897. https://doi.org/10.1039/D2CS00141A
|
[28]
|
Hong, K.B. and An, H. (2023) Degrader-Antibody Conjugates: Emerging New Modality. Journal of Medicinal Chemistry, 66, 140-148. https://doi.org/10.1021/acs.jmedchem.2c01791
|
[29]
|
Dragovich, P.S., Pillow, T.H., Blake, R.A., Sadowsky, J.D., Adaligil, E., Adhikari, P., Chen, J., Corr, N., Dela Cruz-Chuh, J., Del Rosario, G., Fullerton, A., Hartman, S.J., Jiang, F., Kaufman, S., Kleinheinz, T., Kozak, K.R., Liu, L., Lu, Y., Mulvihill, M.M., Murray, J.M., O’Donohue, A., Rowntree, R.K., Sawyer, W.S., Staben, L.R., Wai, J., Wang, J., Wei, B., Wei, W., Xu, Z., Yao, H., Yu, S.F., Zhang, D., Zhang, H., Zhang, S., Zhao, Y., Zhou, H. and Zhu, X. (2021) Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of in Vitro Antiproliferation Activity and in Vivo Antitumor Efficacy. Journal of Medicinal Chemistry, 64, 2576-2607. https://doi.org/10.1021/acs.jmedchem.0c01846
|
[30]
|
Dragovich, P.S., Adhikari, P., Blake, R.A., Blaquiere, N., Chen, J., Cheng, Y.X., den Besten, W., Han, J., Hartman, S.J., He, J., He, M., Rei Ingalla, E., Kamath, A.V., Kleinheinz, T., Lai, T., Leipold, D.D., Li, C.S., Liu, Q., Lu, J., Lu, Y., Meng, F., Meng, L., Ng, C., Peng, K., Lewis Phillips, G., Pillow, T.H., Rowntree, R.K., Sadowsky, J.D., Sampath, D., Staben, L., Staben, S.T., Wai, J., Wan, K., Wang, X., Wei, B., Wertz, I.E., Xin, J., Xu, K., Yao, H., Zang, R., Zhang, D., Zhou, H. and Zhao, Y. (2020) Antibody-Mediated Delivery of Chimeric Protein Degraders Which Target Estrogen Receptor Alpha (ERα). Bioorganic & Medicinal Chemistry Letters, 30, Article ID: 126907. https://doi.org/10.1016/j.bmcl.2019.126907
|